Alnylam receives positive chmp opinion for vutrisiran for the treatment of hereditary transthyretin-mediated (hattr) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has adopted a positive opinion recommending approval of vutrisiran, an rnai therapeutic for the treatment of hereditary transthyretin-mediated (hattr) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. if approved by the european commission (
ALNY Ratings Summary
ALNY Quant Ranking